跳至主要内容
临床试验/NCT03046238
NCT03046238Unknown3 期

Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block in Patient Undergoing Breast Cancer Surgery :A Comparative Study

South Egypt Cancer Institute1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2017年2月2日最近更新:
适应症
干预措施

试验速览

阶段
3 期
发起方
入组人数
60
试验地点
1
主要终点
Visual Analog Scale (VAS), scored from 0-10

研究概览

简要总结

To Evaluate the effect of addition of Dexmedetomedine to ultrasound guided modified Pecs block on post operative analgesia & stress response in patient undergoing modified radical mastectomy.

详细描述

60 patients (age ≥29 years) who scheduled for modified radical mastectomy surgery under general anesthesia. Group I (Bupivacaine group): patients underwent modified radical mastectomy were given preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine divided into 10 ml injected between the pectoralis muscles on the interfasial plane, and 20 ml injected between the Pectoralis minor muscle and the serratus muscle.Group II (Bupivacaine + Dexmedetomidine group) : preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg) divided into 20 ml injected between the pectoralis muscles on the interfasial plane , and 10 ml injected between the Pectoralis minor muscle and the serratus muscle.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • ASA I - II patients
  • weight 50- 100 kg)

排除标准

  • a history of bleeding diathesis,
  • relevant drug allergy
  • opioid dependence,
  • those with psychiatric illnesses

研究组 & 干预措施

dexmetedomedine

Active Comparator

preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg)

干预措施: Dexmedetomidine (Drug)

control

Placebo Comparator

preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine

干预措施: placebo (Drug)

结局指标

主要结局

Visual Analog Scale (VAS), scored from 0-10

时间窗: 48 hours

pain measurement

morphine consumption mg/day

时间窗: 48 HOURS

by Patient-controlled analgesia (PCA) device

次要结局

  • first request of analgesia(48 hours)
  • level of stress hormones(48 hours)
  • Adverse Events(48 hours)

研究者

发起方
South Egypt Cancer Institute
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr.mohamad farouk mohamad

lecturer of anesthesia,ICU and pain relief

South Egypt Cancer Institute

研究点 (1)

Loading locations...

相似试验